Jupiter Life Lin Q1 FY27 Results (NSE: JLHL)
Signal: Margin pressure
The read
Consolidated revenue +16.5% YoY (decelerating from +22% in Q1FY26), OPM contracted 120bps — third quarter of margin compression in the trailing five quarters — as employee & finance costs outpaced growth; PAT growth 5.6% lagged revenue; EPS flat due to dilution.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹41.1 Cr | 16.5% | 6.0% |
| EBIT | ₹7.96 Cr | 6.9% | |
| Net profit | ₹6.52 Cr | 5.6% | |
| EPS | ₹9.97 | 0.2% | |
| EBIT margin | 18.9% |
P&L walk
Revenue grew 16.5% YoY — moderate, but OPM contracted 120bps as employee costs (+20% YoY) and finance costs (+30% YoY) outpaced revenue growth; PAT growth lagged (5.6%) due to higher depreciation; no operating leverage.
Segments
No reportable segments — single-segment healthcare services, hotel division below 10% threshold.
Key positives
- Revenue growth of 16.5% YoY maintained, driven by volume and ARPOB.
- Acquisition of Sulcus Private Limited expands pharmacy footprint, adding potential scale.
- Depreciation as % of revenue stable at 6.3% — asset base being utilised efficiently.
Key concerns
- OPM contracted 120bps YoY to 18.9% — employee cost % up 100bps, finance cost % up 50bps.
- PAT growth (5.6%) lagged revenue growth significantly.
- EPS diluted (0.2% growth) despite PAT growth — subsidiary equity dilution.
Research and educational content only. Not investment advice.